Ironwood Pharmaceuticals (IRWD) PT Raised to $27 at Mizuho Securities

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Ironwood Pharmaceuticals (IRWD) PT Raised to $27 at Mizuho Securities

Ironwood Pharma (IRWD) Misses Q2 EPS by 4c, Revenues Miss; Offers 2018 Guidance

August 6, 2018 8:02 AM EDT

Ironwood Pharma (NASDAQ: IRWD) reported Q2 EPS of ($0.25), $0.04 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $81 million versus the consensus estimate of $82.6 million.

Second quarter revenue increased 25% year-over-year to $81 million, driven primarily by LINZESS® (linaclotide) U.S. net sales of $192 million and commercial margin of 60% Terminating licensing agreement with AstraZeneca for U.S. lesinurad franchise Initiated Phase III programs with IW-3718 and linaclotide and advanced four Phase II... More